Deletion of platelet-derived growth factor receptor-β improves diabetic nephropathy in Ca²⁺/calmodulin-dependent

H Suzuki1, I Usui, I Kato

  • 1First Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.

Diabetologia
|August 12, 2011
PubMed
Abstract

Insights

Platelet-derived growth factor receptor-β (PDGFR-β) signaling contributes to diabetic nephropathy progression. Blocking PDGFR-β in diabetic mice reduced kidney damage and oxidative stress, highlighting its therapeutic potential.

Area of Science:

  • Nephrology
  • Endocrinology
  • Molecular Biology

Background:

  • Diabetic nephropathy is a major complication of diabetes.
  • Platelet-derived growth factor receptor-β (PDGFR-β) signaling is implicated in kidney disease.

Purpose of the Study:

  • To investigate the role of PDGFR-β signaling in the development of diabetic nephropathy.
  • To determine if blocking PDGFR-β can ameliorate kidney damage in a mouse model of diabetes.

Main Methods:

  • Generated CaMKIIα transgenic mice with high glucose levels and diabetic nephropathy features.
  • Created conditional knockout mice with postnatal deletion of the Pdgfr-β gene.
  • Evaluated kidney function and pathology at 10 and 16 weeks of age.

Main Results:

  • Postnatal deletion of Pdgfr-β significantly reduced albuminuria and mesangial expansion in diabetic mice.
  • PDGFR-β gene deletion decreased kidney oxidative stress markers, including 8-hydroxydeoxyguanosine (8-OHdG), NOX4, GPX1, and MnSOD.
  • Plasma glucose levels remained unaffected by Pdgfr-β deletion.

Conclusions:

  • PDGFR-β signaling activation contributes to diabetic nephropathy progression.
  • Targeting PDGFR-β signaling may be a therapeutic strategy for diabetic nephropathy.
  • PDGFR-β plays a role in oxidative stress and mesangial expansion in diabetic kidneys.